Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Garadacimab in Pediatric Hereditary Angioedema
NCT05819775Phase 3Completed
- Sponsor
- CSL Limited
- Start
- May 2023
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 3, open-label, single-arm trial of garadacimab in hereditary angioedema (HAE), sponsored by CSL Limited. Primary endpoints: Number and Percentage of Participants With Treatment Emergent Adverse Events, Maximum Concentration of CSL312 at Steady-state and 2 more. Started May 2023; status: completed.
02
Drugs
garadacimab
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT05819775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05819775.